<<<<<<< HEAD
{"id":128852,"date":"2021-03-10T21:23:24.000Z","description":null,"for":472,"against":214,"abstention":9,"plenary":null,"name":"Proposition de résolution - ","ref":"B9-0162/2021","green_remark":null,"created_by":null,"updated_by":null,"title":"Objection pursuant to Rule 112(2) and (3) on the extension of the approval periods of the active substances benfluralin, dimoxystrobin, fluazinam, flutolanil, mecoprop-P, mepiquat, metiram, oxamyl and pyraclostrobin","url":"https://oeil.secure.europarl.europa.eu/oeil//popups/ficheprocedure.do?reference=2021/2552(RSP)&amp;l=en"}
=======
{"id":128852,"date":"2021-03-10T21:23:24.000Z","description":null,"for":472,"against":214,"abstention":9,"plenary":null,"name":"Objection formulée conformément à l'article 112, paragraphes 2 et 3: substances actives, notamment la dimoxystrobine - Objection pursuant to Rule 112(2) and (3): Active substances, including dimoxystrobin - Einwand gemäß Artikel 112 Absätze 2 und 3 (GO): Wirkstoffe wie Dimoxystrobin -  - Proposition de résolution","ref":"B9-0162/2021","green_remark":null,"created_by":null,"updated_by":null,"title":"Resolution on Commission Implementing Regulation (EU) 2021/52 of 22 January 2021 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances benfluralin, dimoxystrobin, fluazinam, flutolanil, mecoprop-P, mepiquat, metiram, oxamyl and pyraclostrobin","url":"https://oeil.secure.europarl.europa.eu/oeil//popups/ficheprocedure.do?reference=2021/2552(RSP)&amp;l=en"}
>>>>>>> production
